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Introduction:  Wheeze  is  an  important  sign  indicating  a potentially  severe  adverse  event  in vaccine  and
drug  trials,  particularly  in  children.  However,  there  are  currently  no consensus  deﬁnitions  of  wheeze  or
associated  respiratory  compromise  in  randomized  controlled  trials  (RCTs).
Objective: To  identify  deﬁnitions  and  severity  grading  scales  of  wheeze  as  an  adverse  event  in  vaccine  and
drug RCTs  enrolling  children  <5 years  and  to determine  their  diagnostic  performance  based  on  sensitivity,
speciﬁcity  and inter-observer  agreement.
Methods:  We  performed  a systematic  review  of electronic  databases  and  reference  lists  with  restrictions
for  trial  settings,  English  language  and  publication  date  ≥1970.  Wheeze  deﬁnitions  and  severity  grading
were  abstracted  and  ranked  by  a diagnostic  certainty  score  based  on sensitivity,  speciﬁcity  and  inter-
observer  agreement.
Results: Of  1205  articles  identiﬁed  using our  broad  search  terms,  we  identiﬁed  58 eligible  trials  conducted
in  38  countries,  mainly  in high-income  settings.  Vaccines  made  up the  majority  (90%)  of  interventions,
particularly  inﬂuenza  vaccines  (65%).  Only  15  trials  provided  explicit  deﬁnitions  of  wheeze.  Of  24  studies
that  described  severity,  11  described  wheeze  severity  in the  context  of an  explicit  wheeze  deﬁnition.
The  remaining  13  studies  described  wheeze  severity  where  wheeze  was  deﬁned  as  part  of  a  respiratory
illness  or  a wheeze  equivalent.  Wheeze  descriptions  were  elicited  from  caregiver  reports  (14%),  physical
examination  by  a health  worker  (45%)  or a combination  (41%).  There  were  21/58  studies  in which  wheeze
deﬁnitions  included  combined  caregiver  report  and  healthcare  worker  assessment.  The  use  of these  two
methods  appeared  to have  the highest  combined  sensitivity  and  speciﬁcity.
Conclusion:  Standardized  wheeze  deﬁnitions  and  severity  grading  scales  for use  in  pediatric  vaccine  or
drug trials are  lacking.  Standardized  deﬁnitions  of  wheeze  are needed  for  assessment  of possible  adverse
events  as new  vaccines  and drugs  are  evaluated.
ublis©  2015  The  Authors.  P
. Introduction
Wheeze is an important clinical sign of a potential adverse respi-
atory event in pediatric drug and vaccine trials. Reports of wheeze
n children participating in inﬂuenza vaccine trials have raised par-
icular concern of causal associations between vaccine receipt and
∗ Corresponding author. +254 721282815.
E-mail address: marangud@gmail.com (D. Marangu).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
adverse respiratory events [1–4]. However, wheeze deﬁnitions vary
and range from transient audible breath sounds with no associated
respiratory symptoms to the presence of severe respiratory dis-
tress. This is a missed opportunity for consistent case veriﬁcation
and data comparability within and across trials and products.
During the pre-licensure evaluation of the Ann-Arbor backbone
live attenuated inﬂuenza vaccine (LAIV), a safety signal for wheeze
was identiﬁed in children <2 years and among children with a past
history of wheeze and/or asthma [2]. No wheeze signal was  identi-
ﬁed for the Leningrad-backbone LAIV, but the clinical development
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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f this product preceded the Ann-Arbor backbone LAIV and wheez-
ng was not directly solicited as an adverse event in these trials [5].
ecause the burden of inﬂuenza is greatest in children <2 years of
ge [6], determining the safety of LAIV vaccines in this age group
s a priority [7]. In order to conduct safety and efﬁcacy trials of the
eningrad-backbone LAIV and other vaccines in this population, a
onsistent deﬁnition of wheeze is needed.
To inform the development of a standardized deﬁnition of
heeze to be used in clinical trials of Leningrad-backbone LAIV
n young children as well as other trials of vaccines or drugs, we
onducted a systematic review to identify deﬁnitions and severity
rading of wheeze as an adverse event in these settings. In addition,
e assigned scores and ranks based on the diagnostic certainty
f wheeze deﬁnitions to inform recommendations to a Brighton
ollaboration convened working group.
. Methods
.1. Search strategy
We  conducted an electronic literature search on October 28,
014, applying the Patient Population, Intervention, Comparator,
utcome, Timing and Setting (PICOTS) framework [8] outlined in
upplementary Materials Table 1 [38–79]. We  considered stud-
es as the population and case deﬁnitions as the outcomes. We
earched the following clinical databases: MEDLINE, EMBASE, Web
f Science, Scopus, CINAHL Plus, the Cochrane Library databases
nd WHO  Global Health Library. The search was restricted to
nglish language publications and trials published after 1970. We
earched ‘gray literature’ databases, conference abstracts and man-
ally reviewed reference lists of selected publications and records
ecommended by experts to encompass a broad range of the
vailable literature. Wheezing deﬁnitions from the protocols of
wo ongoing studies, and one recently published study were also
ncluded [9–11]. Case reports, case series, cross-sectional, case-
ontrol, cohort or quasi-experimental studies were excluded. Our
earch strategy is in Supplementary Tables 2 and 3. We  merged our
earch results into EndNote (Thomson Reuters, New York, NY) and
emoved duplicate citations.
.2. Population
We  included vaccine and drug randomized controlled trials
RCTs) reporting wheezing or respiratory signs, symptoms and
iseases that were considered “wheeze equivalents” including
sthma and bronchiolitis as an adverse event. We  included stud-
es conducted in inpatient, outpatient, or community settings. We
xcluded studies that did not enroll children <5 years of age. World
ank country income economy classiﬁcation at the time the study
as conducted was used as a proxy for socioeconomic status and
edical resource availability.
.3. Data extraction
Two independent reviewers (D.M., S.K.) screened titles and
bstracts of all citations to identify potentially eligible studies
ﬁrst screen). The second screen consisted of full-text review
f studies selected by either reviewer in the ﬁrst screen with
greement required for ﬁnal study eligibility and inclusion in
he systematic review. Disagreements on study inclusion were
esolved by discussions between the reviewers or by the decision
f a third reviewer (D.J.H.). A log of excluded studies and reasons for
xclusion was kept and is available upon request. The two  review-
rs independently extracted data using a standardized form and
esolved any discrepancies by consensus.3 (2015) 5333–5341
2.4. Outcomes
We  identiﬁed study-speciﬁc wheeze deﬁnitions and wheeze
severity grading scales. If wheeze was  not described, deﬁnition(s) of
pre-deﬁned wheeze equivalents (rhonchi, bronchiolitis, bronchitis,
asthma, reactive airway disease and respiratory hypersensitivity)
were assessed. We  pre-speciﬁed subgroups by age (<2 years, ≥2
years), history of wheeze/asthma, comorbidity status, and cate-
gories of wheeze deﬁnitions (speciﬁc wheeze deﬁnition, wheeze
assessed without an explicit deﬁnition and other wheeze equiva-
lents).
When possible, we evaluated each included study to determine
whether and to what extent U.S. National Institutes of Health, Divi-
sion of AIDS (DAIDS) severity grades [12] were assessed in the
context of wheeze or wheeze equivalents. The DAIDS severity grad-
ing for adverse event deﬁnitions is a widely used severity grading
scale for respiratory events in clinical trials. This grading system for
adverse events related to dyspnea or respiratory distress in patients
<14 years deﬁnes grade 1 as “wheezing OR minimal increase in
respiratory rate for age”, grade 2 as “nasal ﬂaring OR intercostal
retractions OR pulse oximetry 90–95%”, grade 3 as “dyspnea at rest
causing inability to perform usual social and functional activities
OR pulse oximetry <90%”, and grade 4 as “respiratory failure with
ventilation support indicated”.
In addition, we  ranked wheeze deﬁnitions by a diagnostic
certainty score, developed for the purpose of this review. The
diagnostic certainty score is based on performance in three cate-
gories: sensitivity, speciﬁcity, and inter-observer agreement (high,
moderate, low). Each category grade is converted to a numeric
score (high = 2, moderate = 1 and low = 0), and summed to create
a diagnostic certainty score with a range from 0 to 6 points. The
diagnostic certainty score is based on the detection of any wheeze,
regardless of severity or clinical importance. We  assumed that
formalization and/or veriﬁcation of clinician diagnosed wheeze
improved speciﬁcity and reproducibility, e.g. use of an algorithm,
second clinician conﬁrmation, computer-assisted techniques, and
severity assessment. We  made assumptions that: (1) physicians
and healthcare workers assessing wheeze were well-trained, (2)
caregivers identify symptoms of respiratory illness without the
aid of a stethoscope and (3) active surveillance is likely to
pick up more wheeze cases including those that are not severe,
in comparison to healthcare worker or caregiver assessments
alone.
2.5. Analysis
We  analyzed the identiﬁed outcomes by the following pro-
cedures: (1) enumeration of studies grouped by outcome type
(wheeze deﬁned, wheeze equivalent(s) deﬁned, and wheeze or
wheeze equivalent(s) assessed without explicit deﬁnition); (2)
classiﬁcation of wheeze and wheeze equivalent by assessor type
and qualiﬁcations, method of wheeze detection, timing and opera-
tionalization of assessment; (3) enumeration of studies providing
data on wheeze and wheeze equivalent severity; (4) determination
of ability to assign study measures of severity to a DAIDS grade; and
(5) ranking of wheeze deﬁnitions based on the proposed diagnostic
certainty score.
3. ResultsWe  identiﬁed 1205 citations from an electronic database search,
of which 335 studies were selected for full text review. A total of
58 studies were included in the ﬁnal synthesis as depicted in the
PRISMA ﬂow chart (Fig. 1).
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.1. Wheeze description statistics
Approximately 70% of trials were conducted in North America
23), Europe (17) and Australia (7) as illustrated in Fig. 2. Less than
0% of included trials were from low income and lower middle
ncome countries. Most (80%) of the trials in this systematic review
ncluded children <2 years. In studies including children ≥2 years,
0% excluded children with a history of wheeze. All studies that
ncluded children <2 years of age excluded children with a his-
ory of wheeze. The majority (90%) of study interventions were
accines, with the remainder being intervention trials for Flutica-
one, Immunoglobulin, Sublingual immunotherapy, Lactobacillus,
ycobacterium phlei, mattress covers and dust mite control. Of the
1 included vaccine trials, 33 involved inﬂuenza vaccines (65%)
ith the remainder vaccines against bacteria (20%), viruses other
han inﬂuenza (12%), Mycobacterium tuberculosis (2%), and Plas-
odium falciparum (2%). Inﬂuenza vaccine was the most common
ntervention among the pediatric drug and vaccine trials identiﬁed
Fig. 3).A wheeze deﬁnition was provided in 26% of the trials
Supplementary Table 4a) and 45% of the trials assessed wheeze
s a sign or part of a respiratory illness without an explicit def-
nition (Supplementary Table 4b). Wheeze was  not assessed inow chart.
almost one-third of trials (29%) but other wheeze equivalents were
described (Supplementary Table 4c). Supplementary Tables 4a, 4b,
and 4c provide results stratiﬁed by age (children <2 years and chil-
dren ≥2 years). The characteristics of the wheeze deﬁnitions are
summarized in Table 1. Most (69%) studies involved health worker
assessments. Almost half the studies that involved health workers
did not specify their level of training: 52% in studies including chil-
dren <2 years of age and 25% in those excluding this age group. One
out of 3 trials either had wheeze assessed by a health worker or by
a combination of a caregiver and health worker.
Of the 58 studies, few reported on audible wheeze without
a stethoscope (7%), wheeze on auscultation (14%), and detailed
auscultation ﬁndings (7%). These characteristics were more often
reported in trials that excluded children <2 years (25% of studies
in older populations). Four studies provided detailed auscultation
ﬁndings, 2 of which are ongoing studies [9,10], and included chil-
dren 24–59 months [3]. Only one study documented bronchodilator
response. Additional tests in a few studies included pulmonary
function tests and plethysmography (Table 2). Reference to timing
of wheeze or wheeze equivalents as an adverse event was made
in 7 of the 58 studies identiﬁed (12%), and spanned minutes, days,
weeks, months and years (Table 1). In inﬂuenza vaccine studies,
the spectrum of timing of wheeze or wheeze equivalents included
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Fig. 2. Geographical location of all trial sites. Note: The boundaries and names shown and the designations used on this map  do not imply the expression of any opinion
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0 min  to 42 days after the intervention (Supplementary Table 5).
ome studies contacted caregivers via telephone (5%) or home visits
5%), but the majority of studies were facility/site based (69%).
.2. Severity assessment of wheeze
Only 28% of studies described the severity of respiratory
ystem ﬁndings and even fewer studies (7%) documented sever-
ty assessment speciﬁc to wheeze outcomes. While all studies
mong older populations (>2 years old) included descriptions of
everity assessment speciﬁc to wheeze, wheeze-speciﬁc severity
0
Resu lting  in  Death
Unscheduled  health worker visit/ medically attended/life threatening
Required medication/bronchodilator
Hypoxemia on  blood gas analysis
Hypoxia on pulse ox imetry
Cli nic al cy anosi s
Inability to talk/drink/breastfeed
Grunting
Lower chest wall indr awin g
Tachypnea
Frequency of  episod es
Number  of  Studies  (N
Supplementary Table 4a Studies (<2yrs)
Supplement ary Ta ble 4b  Studi es (<2y rs)
Fig. 3. Frequency chart of severity comy country, territory, city or area or of its authorities, or concerning the delimitation
assessments were only provided in 25% of trials that included chil-
dren <2 years (Supplementary Table 5). Descriptions of severity
included frequency of wheeze episodes, features of respiratory dis-
tress including: tachypnea, lower chest wall indrawing, grunting,
inability to breastfeed/drink/talk; hypoxia evidenced by clinical
cyanosis, pulse oximetry or blood gas analysis; hospitalization:
seeking an unscheduled hospital visit, “medically attended” or
life threatening; and those associated with death (Fig. 2 and
Supplementary Table 6). In addition, when the DAIDS severity
grading was applied to studies reporting wheeze severity, trials
that excluded children <2 years more frequently included wheeze
2015105
=24)
Supplementary Table 4a  Studi es (≥2yrs)
Supplementar y Table 4c  Studi es (≥2yrs)
ponents of wheeze deﬁnitions.
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Table  1
Characteristics of wheeze deﬁnitions in trial settings that include children <5 years.
Characteristics of wheeze deﬁnitions Frequency (Supplementary
Table 4a studies)
Assessor qualiﬁcations
Caregiver (parent/guardian) 21 (7)
Health worker 40 (9)
Health worker qualiﬁcations
Physician 10 (5)
Study nurse 3 (0)
Health worker (description not
provided)
27 (7)
Number of assessors
1 assessor – caregiver only 5 (1)
1  assessor – health worker only 20 (7)
>1  assessor – both caregiver and
health worker
21 (4)
Health worker examination details
Wheeze audible without a
stethoscope
5 (4)
Wheeze on auscultation 9 (6)
Characteristic ﬁndings of wheeze on
auscultation
4  (4)
Bronchodilator response 1 (0)
Additional tests: pulmonary function
testa/plethysmographyb
3 (1)
Timing of wheeze or wheeze equivalent
Reference made to timing of wheeze
or wheeze equivalent
7 (4)
Within minutes/hours 1 (1)
Within days 1 (0)
Within weeks 1 (0)
Within months 3 (2)
Within years 1 (1)
Operationalization of assessment
Questionnaire 4 (1)
Diaries/checklists/symptom score
cards
9  (4)
Telephone interview/contact 3 (0)
Home visits 5 (1)
Facility based patient presentation 40 (11)
ICD-9 codes for asthma/reactive 2 (1)
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aairway disease/medically attended
acute respiratory illness
escriptions that allowed detection of all 4 grades of severity (75%),
s compared to studies that included children <2 years (0%).
.3. Diagnostic certainty
Table 2 presents our ranking of diagnostic certainty based
n sensitivity, speciﬁcity and reproducibility of different wheeze
ssessments. The highest scoring wheeze classiﬁcation used a com-
ination of parental report of any respiratory illness (using a diary
r other memory aid), active surveillance, (examination by a clin-
cian) and veriﬁcation (using a computer assisted technique, a
econd clinician or an algorithmic approach). No studies included in
his systematic review used a combination of all three components
report, active surveillance and veriﬁcation). Six additional wheeze
eﬁnitions were given a diagnostic certainty score of 5, including
he use of daily clinical observation [13] and daily active telephone
urveillance [14]. The lowest ranked deﬁnition was the combina-
ion of parental recording of any serious adverse event and passive
urveillance [15].
. Discussion
This systematic review of existing wheeze deﬁnitions and sever-
ty grading scales in pediatric vaccine and drug intervention trials
ncluding children <5 years demonstrates several important gaps in
he current literature. First, wheeze as an adverse event has been
lmost exclusively assessed in trials from high resource settings.3 (2015) 5333–5341 5337
In addition, a standardized deﬁnition and assessment of wheeze
is lacking. Finally, wheeze severity as a proxy for respiratory com-
promise is inconsistently assessed in spite of the availability of a
commonly used severity grading system.
4.1. Deﬁnition
The heterogeneity in wheeze deﬁnitions identiﬁed in this sys-
tematic review may  reﬂect the different etiologies of wheeze. For
this review, we  were speciﬁcally interested in acute onset diffuse
airway narrowing consistent with bronchiolitis, asthma or reactive
airway disease. However, wheeze is non-speciﬁc and may be due
to other acute pathology, including the presence of foreign bodies,
mucous plugs, and pulmonary edema, as well as chronic obstructive
airway disease. The diverse deﬁnitions also reﬂect the wide spec-
trum of clinical presentation of obstructive airway disease. Timing
within the context of the deﬁnition of wheeze as an adverse event
in the pediatric drug and vaccine trials varied widely from minutes,
days, weeks, months to years; even within same type of interven-
tion as shown in the inﬂuenza vaccine trials. This raises the question
on what the optimal timing of assessing wheeze as an adverse event
is, which may  depend on the etiology. In future clinical trials, it may
also be important to come to a consensus on what the best way of
framing (for example acute or delayed wheeze) and further deﬁning
timing in relation to wheeze deﬁnitions.
4.2. Severity
Few studies in this review described an assessment of wheeze
severity and there was  wide variability in how wheeze severity
is captured and described. Classiﬁcations provided were diverse,
including components of the severity classiﬁcation of pneumonia
by WHO  [16] and asthma by the Global Initiative for Asthma (GINA)
[17]. When the DAIDS classiﬁcation for respiratory adverse events
in children <14 years was applied, very few studies were able to
detect all 4 grades of respiratory distress severity. Deﬁnitions of
wheeze as an adverse event beneﬁt from the development of a clear
and consistent severity grading reﬂecting degrees of respiratory
compromise.
Although we  used DAIDS grading in determining the adequacy
of individual study wheeze severity assessment, this classiﬁca-
tion system may  not be ideal for grading severity of wheeze
in trials, given the potential for differential adverse events in
children, particularly those <2 years. In addition, DAIDS grade 3
includes inability to perform usual social activities, which may
require more speciﬁc details for children, such as the inability to
drink/breastfeed. Of note, recently completed LAIV trials [9,11,18]
deﬁned wheezing illness in their protocols and included a spectrum
of severity ranging from mild to life threatening.
Another challenge for deﬁning and grading diseases with reac-
tive airways is that wheeze may  be absent in the most severe
presentations due to airﬂow limitation. Despite these challenges,
wheeze is an important sign of respiratory illness, has been associ-
ated with certain vaccine receipt in the past, and suitable for vaccine
and drug safety monitoring. This systematic review highlights the
need for a consistent, easy to implement, accurate deﬁnition that
is correlated with clinical illness to be used in pediatric trials.
4.3. Diagnostic certainty score
The diagnostic certainty score developed for this study facil-
itated assessment of available deﬁnitions and scoring systems
(Table 2) and may  be useful to guide the development of a standard-
ized case deﬁnition. Wheeze in articles included in this review was
assessed by caregivers and/or healthcare workers. Caregiver report
of respiratory symptoms or abnormalities may be more sensitive
5338 D. Marangu et al. / Vaccine 33 (2015) 5333–5341
Table 2
Proposed ranking of diagnostic certainty for wheeze deﬁnitions in pediatric vaccine and drug trials.
Wheeze deﬁnition Sensitivity Speciﬁcity Inter rater agreement Diagnostic certainty
(range 0–6)
Example study
Combined caregiver report and health worker assessment
Caregiver report using diary or other
memory aid, active surveillance, and
follow-up with clinician. Clinician
diagnosed wheeze veriﬁed by
computer assisted technique/2
clinicians/algorithmic approach.
High High High 6 Not used in a study
Caregiver report using diary or other
memory aid, active surveillance, and
follow-up with clinician
High High Moderate 5 Not used in a study
Active surveillance for wheeze via
phone calls, followed by visit by
study nurse
High High Moderate 5 Piedra, 1996 [31]
Health worker assessment
Clinician diagnosed wheeze veriﬁed
by computer assisted technique
Moderate High High 5 Not used in a study
Wheeze veriﬁed by two physicians Moderate High High 5 Not used in a study
Clinician diagnosed wheeze
employing an algorithmic approach
Moderate High High 5 Not used in a study
Medically attended wheeze –
deﬁned as presence of wheezing on a
physical examination conducted by a
health care provider, for a patient
with signs of respiratory distress
[severity assessment]
Moderate High High 5 Belshe, 1982 [32]
Daily clinical observation Moderate High Moderate 4 Wright, 1976 [13]
Physician veriﬁed wheeze (no
required severity)
Moderate High Moderate 4 Custovic, 2002 [33]
Surveillance of medical visits to
hospitals and emergency rooms for
wheeze asthma and other
respiratory symptoms
Moderate High Moderate 4 Bergen, 2004 [2]
Clinical observation immediately
after vaccine administration
Low High Moderate 3 Greenhawt, 2012 [34]
Retrospective review of ICD-9 codes
for asthma or reactive airway disease
Low High Moderate 2 Gaglani 2008 [4]
Caregiver report
Asthma symptoms assessed using
ISAAC questionnaire by parent
High Low High 4 Kiraly, 2013 [35]
Caregiver report using diary or other
memory aid, and active surveillance
via daily or weekly telephone calls
High Moderate Moderate 4 Esposito 2003 [36]
Daily active surveillance for
respiratory symptoms including
wheeze by telephone by study staff
High Moderate Moderate 4 Anderson, 1992 [14]
Caregiver report using a diary or
other memory aid
Moderate Low Low 1 Rose, 2010 [37]
Caregiver recording of any serious
adverse events and passive
surveillance
Low Low Low 0 Tam, 2007 [15]
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vcoring: high = 2; moderate = 1; low = 0. Add scores across all three components of d
ny  wheeze. Scores assumed healthcare workers are well trained.
hen compared to health worker assessment, as it captures wheeze
nd non-wheeze signs, but may  lack speciﬁcity [19–21]. Respira-
ory questionnaires and the use of videos have been validated to
mprove the accuracy and reliability of caregiver-reported wheeze
22,23]. In contrast, we expect that wheeze identiﬁed on exami-
ation by healthcare workers will be more speciﬁc than caregiver
ssessment, but may  miss community cases and have decreased
ensitivity. Data on the health worker assessment of wheeze in chil-
ren from observational studies in reference to a health worker
f a higher level of training or computer assisted techniques is
lso conﬂicting [24,25]. Health worker training and formal stan-
ardization of assessments of dyspneic wheezing children [26] and
eriﬁcation by multiple healthcare workers may  improve diag-
ostic accuracy and inter-observer reliability. Modern computer
ssisted techniques may  also help assess wheeze and provide
bjectivity currently lacking in existing methods [27,28]. Con-
ersely, an objective approach to wheeze assessment may  require atic certainty. Higher scores = higher diagnostic certainty. All scores are for assessing
simple algorithmic approach to lung sounds in children regardless
of terminology [29,30].
Our results suggest that where resources permit, a three-stage
assessment of wheeze that includes detection of acute respiratory
illness by caregivers, conﬁrmation of wheeze upon clinical exami-
nation by healthcare workers, and wheeze validation using speciﬁc
tools or additional conﬁrmation by another health worker opti-
mizes sensitivity and speciﬁcity of wheezing illness as an adverse
event in pediatric trials.
While this review had several strengths, including the use of
a broad search strategy to capture relevant studies documenting
wheeze deﬁnitions and severity grading, there were also some
limitations. Only English language publications were assessed,
which may  have contributed to some language bias. Trials involv-
ing drugs that were not indexed as therapeutic use, therapy or
treatment outcome may  have been omitted. Although included
studies may  not have reported details of wheeze deﬁnitions in the
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anuscripts, they may  have been available to the investigators,
otentially leading to misclassiﬁcation of wheeze deﬁnitions and
everity assessment in our report.
. Recommendations
A standard deﬁnition of wheeze that includes a severity scale of
espiratory compromise would be useful for clinical trials and post-
icensure vaccine and drug safety surveillance of pediatric popu-
ations. Wheeze may  indicate the presence of serious illness and
hould be detected early in clinical trials. With new drugs and vac-
ines in the pipeline targeted for use in low-income countries, there
s a need for a standardized, consensus deﬁnition that can be easily
perationalized. In addition, we recommend that any wheeze deﬁ-
ition should leverage a three-stage assessment design to improve
ensitivity, speciﬁcity and inter-observer agreement. Including
aregiver report of wheeze and other symptoms of respiratory
llness and active surveillance with health care worker clinical eval-
ation and veriﬁcation of clinician diagnosed wheeze would likely
ptimize both sensitivity and speciﬁcity, leading to higher diagnos-
ic certainty. Finally, wheeze assessment should be implemented
y trained personnel. Wheeze can be difﬁcult to differentiate from
ther respiratory signs and symptoms, particularly in children.
ell-trained caregivers and staff, conversant in identifying wheeze
n children will be needed to accurately detect wheeze in the con-
ext of a clinical trial. We  believe that training health workers may
mprove inter-observer agreement and provide consistency in case
scertainment and data collection across sites and studies.
unding
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